BeOne Medicines FY26 H1 net income climbs to US$464.36 million; revenue rises 32.3% to US$3.22 billion
ONC•Half-year profit and revenue jump
BeOne Medicines posted GAAP net income of US$464.36 million, swinging from a profit of US$95.59 million a year earlier.
Total revenue climbed 32.3% to US$3.22 billion; BRUKINSA revenue rose 34.5% to US$2.34 billion.
Earnings per ADS and cash flow rise
On a GAAP basis, diluted earnings per ADS increased to US$4.01 from US$0.85; free cash flow rose to US$595.89 million.
Margins and operating income improve
Operating income widened to US$574.95 million from US$98.99 million, as gross margin rose 2.9 percentage points to 89.2%.
Recent regulatory and business updates
Recent updates included FDA clearance for a , accelerated approval for in , and a deal.
